Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Dichloroacetate stabilizes the mutant E1alpha subunit in pyruvate dehydrogenase deficiency.
[pyruvate dehydrogenase deficiency]
To
determine
whether
dichloroacetate
(
DCA
)
treatment
can
increase
pyruvate
dehydrogenase
(
PDH
)
activity
in
PDH
-
deficient
cell
lines
harboring
pathogenic
mutations
in
the
PDH
E
1
alpha
gene
.
P
DH
deficiency
is
a
nuclear-encoded
mitochondrial
disorder
and
a
major
recognized
cause
of
neonatal
encephalomyopathies
associated
with
primary
lactic
acidosis
.
Over
the
last
decade
,
DCA
has
been
used
therapeutically
,
but
it
has
not
been
clear
which
patients
might
benefit
.
Recent
studies
suggest
that
chronic
DCA
treatment
may
act
by
increasing
the
stability
of
mutant
E
1
alpha
polypeptide
.
The
relative
effects
of
DCA
treatment
on
PDH
-
deficient
cell
lines
with
E
1
alpha
mutations
primarily
affecting
polypeptide
stability
or
catalytic
activity
were
determined
and
the
mechanism
of
enhancement
of
residual
PDH
activity
explored
.
The
effect
of
chronic
5
-
day
DCA
treatment
on
PDH
activity
was
assessed
in
PDH
-
deficient
cell
lines
containing
the
R
378
H
,
R
141
Q
,
K
387
(
FS
)
,
and
R
302
C
E
1
alpha
mutations
.
PDH
subunit
turnover
and
steady-
state
E
1
alpha
levels
before
and
after
DCA
treatment
were
measured
in
the
R
378
H
mutant
line
.
C
hronic
DCA
treatment
resulted
in
25
%
(
p
=
0
.
0434
)
,
31
%
(
p
=
0
.
0014
)
increases
in
PDH
activity
in
the
K
387
(
FS
)
and
R
378
H
cell
lines
,
both
of
which
are
associated
with
decreased
mutant
polypeptide
stability
.
In
the
R
378
H
mutant
cell
line
,
chronic
DCA
treatment
increased
steady-
state
E
1
alpha
levels
and
slowed
the
rate
of
E
1
alpha
turnover
twofold
.
In
contrast
,
PDH
activity
did
not
change
in
the
chronically
DCA-treated
R
302
C
mutant
line
,
in
which
the
mutant
polypeptide
has
normal
stability
and
reduced
catalytic
activity
.
Chronic
DCA
treatment
can
increase
PDH
activity
in
PDH
-
deficient
cell
lines
harboring
mutations
that
affect
E
1
alpha
stability
,
suggesting
a
biochemical
criterion
by
which
DCA-responsive
patients
might
be
selected
.
Diseases
Validation
Diseases presenting
"a major recognized cause of neonatal encephalomyopathies associated with primary lactic acidosis"
symptom
pyruvate dehydrogenase deficiency
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom